Stephen R. Zukin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Stephen R. Zukin has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
D C Javitt
Department of Psychiatry, Albert Einstein College of Medicine, Bronx Psychiatric Center, NY 10461
9 shared publicationsRatna Sircar
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY U.S.A.
9 shared publicationsR. Suzanne Zukin
7 shared publicationsDaniel C. Javitt
4 shared publicationsS R Zukin
4 shared publicationsAnne B. Young
3 shared publications
Latest Publications
- Open Access
- 1 November 2015
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 25 (11) , 1882-1891
Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials
- 1 November 2015
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 25 (11) , 1882-1891
Open AccessEffect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials
- 1 September 2015
- Published by Elsevier in Clinical Therapeutics
- Vol. 37 (9) , 2059-2070
Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition
- 1 September 2015
- Published by Elsevier in Clinical Therapeutics
- Vol. 37 (9) , 2059-2070
Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition
- 1 August 2015
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 35 (4) , 367-373
Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia
This phase III study evaluated the efficacy and safety of cariprazine, a dopamine D3 and D2 receptor partial agonist with preferential binding to D3 receptors, in patients with acute exacerbation of schizophrenia. Patients were randomized to 6-week double-blind treatment with placebo, cariprazine 3 to 6 mg/d, or cariprazine 6 to 9 mg/d. Primary and secondary efficacy: change from baseline to week 6 in Positive and Negative Syndrome Scale total and Clinical Global Impressions-Severity scores, respectively, analyzed using a mixed-effects model for repeated measures adjusting for multiple comparisons. Safety included treatment-emergent adverse events, clinical laboratory values, vital signs, electrocardiograms, ophthalmologic examination, Columbia-Suicide Severity Rating Scale, and extrapyramidal symptom scales. In the Safety Population (placebo, n = 147; cariprazine 3-6 mg/d, n = 151; cariprazine 6-9 mg/d, n = 148), 60.5% of patients completed the study. At week 6, statistically significant least squares mean differences in favor of cariprazine versus placebo were observed for Positive and Negative Syndrome Scale total score (3-6 mg/d: -6.8, P = 0.003; 6-9 mg/d: -9.9, P < 0.001) and Clinical Global Impressions-Severity (3-6 mg/d: -0.3, P = 0.012; 6-9 mg/d: -0.5, P < 0.001). Common treatment-emergent adverse events (≥5% and twice the rate of placebo) in both cariprazine groups were akathisia, extrapyramidal disorder, and tremor; most were mild to moderate in severity. Mean changes in metabolic parameters were generally small and similar between groups. Prolactin levels decreased in all groups. In conclusion, cariprazine 3 to 6 and 6 to 9 mg/d versus placebo demonstrated significant improvement on primary and secondary efficacy parameters. Cariprazine was generally well tolerated. These results suggest that cariprazine may be a new and effective treatment for schizophrenia.
- 1 August 2015
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 35 (4) , 367-373
Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia
This phase III study evaluated the efficacy and safety of cariprazine, a dopamine D3 and D2 receptor partial agonist with preferential binding to D3 receptors, in patients with acute exacerbation of schizophrenia. Patients were randomized to 6-week double-blind treatment with placebo, cariprazine 3 to 6 mg/d, or cariprazine 6 to 9 mg/d. Primary and secondary efficacy: change from baseline to week 6 in Positive and Negative Syndrome Scale total and Clinical Global Impressions-Severity scores, respectively, analyzed using a mixed-effects model for repeated measures adjusting for multiple comparisons. Safety included treatment-emergent adverse events, clinical laboratory values, vital signs, electrocardiograms, ophthalmologic examination, Columbia-Suicide Severity Rating Scale, and extrapyramidal symptom scales. In the Safety Population (placebo, n = 147; cariprazine 3-6 mg/d, n = 151; cariprazine 6-9 mg/d, n = 148), 60.5% of patients completed the study. At week 6, statistically significant least squares mean differences in favor of cariprazine versus placebo were observed for Positive and Negative Syndrome Scale total score (3-6 mg/d: -6.8, P = 0.003; 6-9 mg/d: -9.9, P < 0.001) and Clinical Global Impressions-Severity (3-6 mg/d: -0.3, P = 0.012; 6-9 mg/d: -0.5, P < 0.001). Common treatment-emergent adverse events (≥5% and twice the rate of placebo) in both cariprazine groups were akathisia, extrapyramidal disorder, and tremor; most were mild to moderate in severity. Mean changes in metabolic parameters were generally small and similar between groups. Prolactin levels decreased in all groups. In conclusion, cariprazine 3 to 6 and 6 to 9 mg/d versus placebo demonstrated significant improvement on primary and secondary efficacy parameters. Cariprazine was generally well tolerated. These results suggest that cariprazine may be a new and effective treatment for schizophrenia.
- Open Access
- 28 May 2015
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 35 (7) , 427-435
A Novel Once-Daily Fixed-Dose Combination of Memantine Extended Release and Donepezil for the Treatment of Moderate to Severe Alzheimer’s Disease: Two Phase I Studies in Healthy Volunteers
Background Combining two standard-of-care medications for Alzheimer’s disease (AD) into a single once-daily dosage unit may improve treatment adherence, facilitate drug administration, and reduce caregiver burden. A new fixed-dose combination (FDC) capsule containing 28 mg memantine extended release (ER) and 10 mg donepezil was evaluated for bioequivalence with co-administered commercially available memantine ER and donepezil, and for bioavailability with regard to food intake. Methods Two phase I, single-dose, randomized, open-label, crossover studies were conducted in 18- to 45-year-old healthy individuals. In MDX-PK-104 study, fasting participants (N = 38) received co-administered memantine ER and donepezil or the FDC. In MDX-PK-105 study, participants (N = 36) received three treatments: intact FDC taken while fasting or after a high-fat meal, or FDC contents sprinkled on applesauce while fasting. Standard pharmacokinetic parameters for memantine and donepezil were calculated from the plasma concentration time-curve using non-compartmental analyses. Linear mixed-effects models were used to compare: (a) FDC versus co-administered individual drugs; (b) FDC fasted versus with food; and (c) FDC sprinkled on applesauce versus FDC intact, both fasted. Safety parameters were also evaluated. Results The FDC capsule was bioequivalent to co-administered memantine ER and donepezil. There was no significant food effect on the bioavailability of the FDC components. There were no clinically relevant differences in time to maximum plasma concentration or safety profiles across treatments. Conclusions An FDC capsule containing 28 mg memantine ER and 10 mg donepezil is bioequivalent to commercially available memantine ER and donepezil, and bioavailability is not affected by food intake or sprinkling of capsule contents on applesauce.
- 28 May 2015
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 35 (7) , 427-435
Open AccessA Novel Once-Daily Fixed-Dose Combination of Memantine Extended Release and Donepezil for the Treatment of Moderate to Severe Alzheimer’s Disease: Two Phase I Studies in Healthy Volunteers
Background Combining two standard-of-care medications for Alzheimer’s disease (AD) into a single once-daily dosage unit may improve treatment adherence, facilitate drug administration, and reduce caregiver burden. A new fixed-dose combination (FDC) capsule containing 28 mg memantine extended release (ER) and 10 mg donepezil was evaluated for bioequivalence with co-administered commercially available memantine ER and donepezil, and for bioavailability with regard to food intake. Methods Two phase I, single-dose, randomized, open-label, crossover studies were conducted in 18- to 45-year-old healthy individuals. In MDX-PK-104 study, fasting participants (N = 38) received co-administered memantine ER and donepezil or the FDC. In MDX-PK-105 study, participants (N = 36) received three treatments: intact FDC taken while fasting or after a high-fat meal, or FDC contents sprinkled on applesauce while fasting. Standard pharmacokinetic parameters for memantine and donepezil were calculated from the plasma concentration time-curve using non-compartmental analyses. Linear mixed-effects models were used to compare: (a) FDC versus co-administered individual drugs; (b) FDC fasted versus with food; and (c) FDC sprinkled on applesauce versus FDC intact, both fasted. Safety parameters were also evaluated. Results The FDC capsule was bioequivalent to co-administered memantine ER and donepezil. There was no significant food effect on the bioavailability of the FDC components. There were no clinically relevant differences in time to maximum plasma concentration or safety profiles across treatments. Conclusions An FDC capsule containing 28 mg memantine ER and 10 mg donepezil is bioequivalent to commercially available memantine ER and donepezil, and bioavailability is not affected by food intake or sprinkling of capsule contents on applesauce.
- Open Access
- 17 August 2012
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 38 (5) , 958-966
Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia
Over the last 20 years, glutamatergic models of schizophrenia have become increasingly accepted as etiopathological models of schizophrenia, based on the observation that phencyclidine (PCP) induces a schizophrenia-like psychosis by blocking neurotransmission at N-methyl-D-aspartate (NMDA)-type glutamate receptors. This article reviews developments in two key predictions of the model: first, that neurocognitive deficits in schizophrenia should follow the pattern of deficit predicted based on underlying NMDAR dysfunction and, second, that agents that stimulate NMDAR function should be therapeutically beneficial. As opposed to dopamine receptors, NMDAR are widely distributed throughout the brain, including subcortical as well as cortical brain regions, and sensory as well as association cortex. Studies over the past 20 years have documented severe sensory dysfunction in schizophrenia using behavioral, neurophysiological, and functional brain imaging approaches, including impaired generation of key sensory-related potentials such as mismatch negativity and visual P1 potentials. Similar deficits are observed in humans following administration of NMDAR antagonists such as ketamine in either humans or animal models. Sensory dysfunction, in turn, predicts impairments in higher order cognitive functions such as auditory or visual emotion recognition. Treatment studies have been performed with compounds acting directly at the NMDAR glycine site, such as glycine, D-serine, or D-cycloserine, and, more recently, with high-affinity glycine transport inhibitors such as RG1678 (Roche). More limited studies have been performed with compounds targeting the redox site. Overall, these compounds have been found to induce significant beneficial effects on persistent symptoms, suggesting novel approaches for treatment and prevention of schizophrenia.
- 17 August 2012
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 38 (5) , 958-966
Open AccessHas an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia
Over the last 20 years, glutamatergic models of schizophrenia have become increasingly accepted as etiopathological models of schizophrenia, based on the observation that phencyclidine (PCP) induces a schizophrenia-like psychosis by blocking neurotransmission at N-methyl-D-aspartate (NMDA)-type glutamate receptors. This article reviews developments in two key predictions of the model: first, that neurocognitive deficits in schizophrenia should follow the pattern of deficit predicted based on underlying NMDAR dysfunction and, second, that agents that stimulate NMDAR function should be therapeutically beneficial. As opposed to dopamine receptors, NMDAR are widely distributed throughout the brain, including subcortical as well as cortical brain regions, and sensory as well as association cortex. Studies over the past 20 years have documented severe sensory dysfunction in schizophrenia using behavioral, neurophysiological, and functional brain imaging approaches, including impaired generation of key sensory-related potentials such as mismatch negativity and visual P1 potentials. Similar deficits are observed in humans following administration of NMDAR antagonists such as ketamine in either humans or animal models. Sensory dysfunction, in turn, predicts impairments in higher order cognitive functions such as auditory or visual emotion recognition. Treatment studies have been performed with compounds acting directly at the NMDAR glycine site, such as glycine, D-serine, or D-cycloserine, and, more recently, with high-affinity glycine transport inhibitors such as RG1678 (Roche). More limited studies have been performed with compounds targeting the redox site. Overall, these compounds have been found to induce significant beneficial effects on persistent symptoms, suggesting novel approaches for treatment and prevention of schizophrenia.
- 3 November 2011
- Published by Springer Nature in Psychopharmacology
- Vol. 221 (1) , 39-52
P50 amplitude reduction: a nicotinic receptor-mediated deficit in first-degree relatives of schizophrenia patients
Impaired P50 gating is a putative index of genetically mediated nicotinic dysfunction in schizophrenia. However, assessment is confounded, in patients, by differential effects of smoking, symptoms, and treatment. This double-blind placebo-controlled study was designed to tease apart the relationships among P50, acute and chronic nicotine exposure, and familial risk. Experiment 1: To assess the putative effects of genetic vulnerability without other confounds, 14 unaffected relatives of schizophrenia patients and 15 controls, all nonsmokers, were tested with/without 7 mg transdermal nicotine. Family members had reduced P50 amplitude to an initial auditory stimulus, but normal P50 gating. Nicotine decreased P50 amplitude in controls; family members had a mixed response: eight decreased and six increased P50 amplitude with nicotine. Experiment 2: To assess chronic nicotine use and short-term withdrawal as a model of nicotinic dysfunction, 26 healthy smokers (14 abstinent for >12 h) received 21 mg transdermal nicotine. Chronic nicotine use, alone, did not alter P50 amplitude or gating. Short-term withdrawal resulted in decreased P50 amplitude, with no effect on P50 gating. Nicotine increased P50 amplitude in abstinent smokers and decreased it in nonabstinent smokers. Familial vulnerability to schizophrenia reduces P50 amplitude. Nicotinic modulation of this deficit mirrors the effect of nicotine during smoking abstinence and suggests an “inverted-U” relationship between P50 amplitude and endogenous nicotinic activity. P50 amplitude may, therefore, be a sensitive marker of nicotinic dysfunction in individuals with familial risk for schizophrenia, which is mediated through mechanisms (e.g., α4β2 receptors) that are distinct from those (e.g., α7 receptors) that mediate P50 gating.
- 3 November 2011
- Published by Springer Nature in Psychopharmacology
- Vol. 221 (1) , 39-52
P50 amplitude reduction: a nicotinic receptor-mediated deficit in first-degree relatives of schizophrenia patients
Impaired P50 gating is a putative index of genetically mediated nicotinic dysfunction in schizophrenia. However, assessment is confounded, in patients, by differential effects of smoking, symptoms, and treatment. This double-blind placebo-controlled study was designed to tease apart the relationships among P50, acute and chronic nicotine exposure, and familial risk. Experiment 1: To assess the putative effects of genetic vulnerability without other confounds, 14 unaffected relatives of schizophrenia patients and 15 controls, all nonsmokers, were tested with/without 7 mg transdermal nicotine. Family members had reduced P50 amplitude to an initial auditory stimulus, but normal P50 gating. Nicotine decreased P50 amplitude in controls; family members had a mixed response: eight decreased and six increased P50 amplitude with nicotine. Experiment 2: To assess chronic nicotine use and short-term withdrawal as a model of nicotinic dysfunction, 26 healthy smokers (14 abstinent for >12 h) received 21 mg transdermal nicotine. Chronic nicotine use, alone, did not alter P50 amplitude or gating. Short-term withdrawal resulted in decreased P50 amplitude, with no effect on P50 gating. Nicotine increased P50 amplitude in abstinent smokers and decreased it in nonabstinent smokers. Familial vulnerability to schizophrenia reduces P50 amplitude. Nicotinic modulation of this deficit mirrors the effect of nicotine during smoking abstinence and suggests an “inverted-U” relationship between P50 amplitude and endogenous nicotinic activity. P50 amplitude may, therefore, be a sensitive marker of nicotinic dysfunction in individuals with familial risk for schizophrenia, which is mediated through mechanisms (e.g., α4β2 receptors) that are distinct from those (e.g., α7 receptors) that mediate P50 gating.
- 7 May 2010
- Published by Taylor & Francis in Journal of Clinical and Experimental Neuropsychology
- Vol. 32 (9) , 937-952
A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries
Cognitive impairment is prevalent in schizophrenia and is related to poorer functional and treatment outcomes. Cognitive assessment is therefore now a routine component of clinical trials of new treatments for schizophrenia. The current gold-standard for cognitive assessment in clinical trials for schizophrenia is the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB), which was developed based on expert consensus and incorporates paper-and-pencil tests (and one computerized measure) with an established history in the field of neuropsychology. Recently, however, interest has increased in using computerized batteries for clinical trials. In this study, we tested 155 people with schizophrenia and 75 healthy control participants on both the MCCB and IntegNeuro, a touch-screen-based computerized battery with previously demonstrated high levels of reliability and validity, to determine comparability between test scores. In addition, we assessed test–retest reliability and practice effects over a one-month interval for both batteries and determined correlations between cognitive test scores and scores on functional outcome measures. High levels of agreement were observed between total battery composite scores (r > .80) and, in a canonical correlation analysis, between all critical single test scores from each battery (r c > .90). The batteries demonstrated essentially equivalent sensitivity in discriminating between patients and controls and equivalent levels of test–retest reliability and practice effects. Correlations between cognitive test scores and functional outcome measures were equivalent between the two batteries and low in nearly all cases. The number of missing data points was greater with IntegNeuro, highlighting the requirements for test administrator involvement even with computerized batteries.
- 7 May 2010
- Published by Taylor & Francis in Journal of Clinical and Experimental Neuropsychology
- Vol. 32 (9) , 937-952
A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries
Cognitive impairment is prevalent in schizophrenia and is related to poorer functional and treatment outcomes. Cognitive assessment is therefore now a routine component of clinical trials of new treatments for schizophrenia. The current gold-standard for cognitive assessment in clinical trials for schizophrenia is the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB), which was developed based on expert consensus and incorporates paper-and-pencil tests (and one computerized measure) with an established history in the field of neuropsychology. Recently, however, interest has increased in using computerized batteries for clinical trials. In this study, we tested 155 people with schizophrenia and 75 healthy control participants on both the MCCB and IntegNeuro, a touch-screen-based computerized battery with previously demonstrated high levels of reliability and validity, to determine comparability between test scores. In addition, we assessed test–retest reliability and practice effects over a one-month interval for both batteries and determined correlations between cognitive test scores and scores on functional outcome measures. High levels of agreement were observed between total battery composite scores (r > .80) and, in a canonical correlation analysis, between all critical single test scores from each battery (r c > .90). The batteries demonstrated essentially equivalent sensitivity in discriminating between patients and controls and equivalent levels of test–retest reliability and practice effects. Correlations between cognitive test scores and functional outcome measures were equivalent between the two batteries and low in nearly all cases. The number of missing data points was greater with IntegNeuro, highlighting the requirements for test administrator involvement even with computerized batteries.
- Open Access
- 13 September 2006
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 31 (12) , 2716-2727
Increased Occupancy of Dopamine Receptors in Human Striatum during Cue-Elicited Cocaine Craving
In all, 19 research subjects, with current histories of frequent cocaine use, were exposed to cocaine-related cues to elicit drug craving. We measured the change of occupancy of dopamine at D2-like receptors with positron emission tomography (PET) and inferred a change of intrasynaptic dopamine (endogenous dopamine release), based on the displacement of radiotracer [11C]raclopride. Receptor occupancy by dopamine increased significantly in putamen of participants who reported cue-elicited craving compared to those who did not. Further, the intensity of craving was positively correlated with the increase in dopamine receptor occupancy in the putamen. These results provide direct evidence that occupancy of dopamine receptors in human dorsal striatum increased in proportion to subjective craving, presumably because of increased release of intrasynaptic dopamine.
- 13 September 2006
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 31 (12) , 2716-2727
Open AccessIncreased Occupancy of Dopamine Receptors in Human Striatum during Cue-Elicited Cocaine Craving
In all, 19 research subjects, with current histories of frequent cocaine use, were exposed to cocaine-related cues to elicit drug craving. We measured the change of occupancy of dopamine at D2-like receptors with positron emission tomography (PET) and inferred a change of intrasynaptic dopamine (endogenous dopamine release), based on the displacement of radiotracer [11C]raclopride. Receptor occupancy by dopamine increased significantly in putamen of participants who reported cue-elicited craving compared to those who did not. Further, the intensity of craving was positively correlated with the increase in dopamine receptor occupancy in the putamen. These results provide direct evidence that occupancy of dopamine receptors in human dorsal striatum increased in proportion to subjective craving, presumably because of increased release of intrasynaptic dopamine.
- 25 August 2005
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 3 (10823654) , 1335-1340
Human [/sup 123/I]5-I-A-85380 dynamic SPECT studies in normals: kinetic analysis and parametric imaging
[/sup 123/I]5-I-A-85380 ([/sup 123/I]5-IA) is a ligand specific for the /spl alpha/4/spl beta/2 nicotinic acetylcholine receptor (nAChR) subtype. It was reported that distribution volume (DV) is an appropriate measurement for /spl alpha/4/spl beta/2 nAChR density in baboon [/sup 123/I]5-IA dynamic SPECT studies. To evaluate the kinetics obtained from human [/sup 123/I]5-IA dynamic SPECT, three different methods were applied to region of interest (ROI) kinetics analysis as follows: A: a 2-compartment 3-parameters model, B: 3-compartment 5-parameter model, and C: same model as in B but fitting with a constraint of ratio of K/sub 1//k/sub 2/e estimated by fitting occipital kinetics to model in A. The DV was estimated as DV= K/sub 1//k/sub 2/ for A, and DV=(K/sub 1//k/sub 2/)(1+k/sub 3//k/sub 4/) for B and C. Nonlinear least squares fitting using Marquardt algorithm was performed for A-C. Akaike information criterion (AIC) and R/sup 2/ were used for evaluation of fitting results. A linear parametric imaging algorithm derived from model in method A was used for generating images of K/sub 1/ and DV. Four normal human [/sup 123/I]5-IA dynamic studies were evaluated by A-C. In each study, after a bolus of [/sup 123/I]5-IA (5/spl sim/10 mCi, specific activity>10 Ci/umol) was injected intravenously, a dynamic scanning with 20 acquisitions over 6 hour was started immediately on a Trionix TriadXLT scanner. 30-40 arterial plasma samples were taken during the study and HPLC was performed to determine the metabolite-corrected arterial plasma radioactivity as input function. The ROI regions (cerebellum, frontal cortex, occipital cortex, pones, and thalamus) were drawn on co-registered MRI images. Results show that A fits to all ROI kinetics very well (R/sup 2/>0.99), and paired T-test for AIC showed there is no statistical significantly improvement of model fitting from B, C methods. The K/sub 1/ and DV images are of good image quality. Conclusion: A is best for ROI kinetic analysis and parametric imaging for DV and K/sub 1/.
- 25 August 2005
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 3 (10823654) , 1335-1340
Human [/sup 123/I]5-I-A-85380 dynamic SPECT studies in normals: kinetic analysis and parametric imaging
[/sup 123/I]5-I-A-85380 ([/sup 123/I]5-IA) is a ligand specific for the /spl alpha/4/spl beta/2 nicotinic acetylcholine receptor (nAChR) subtype. It was reported that distribution volume (DV) is an appropriate measurement for /spl alpha/4/spl beta/2 nAChR density in baboon [/sup 123/I]5-IA dynamic SPECT studies. To evaluate the kinetics obtained from human [/sup 123/I]5-IA dynamic SPECT, three different methods were applied to region of interest (ROI) kinetics analysis as follows: A: a 2-compartment 3-parameters model, B: 3-compartment 5-parameter model, and C: same model as in B but fitting with a constraint of ratio of K/sub 1//k/sub 2/e estimated by fitting occipital kinetics to model in A. The DV was estimated as DV= K/sub 1//k/sub 2/ for A, and DV=(K/sub 1//k/sub 2/)(1+k/sub 3//k/sub 4/) for B and C. Nonlinear least squares fitting using Marquardt algorithm was performed for A-C. Akaike information criterion (AIC) and R/sup 2/ were used for evaluation of fitting results. A linear parametric imaging algorithm derived from model in method A was used for generating images of K/sub 1/ and DV. Four normal human [/sup 123/I]5-IA dynamic studies were evaluated by A-C. In each study, after a bolus of [/sup 123/I]5-IA (5/spl sim/10 mCi, specific activity>10 Ci/umol) was injected intravenously, a dynamic scanning with 20 acquisitions over 6 hour was started immediately on a Trionix TriadXLT scanner. 30-40 arterial plasma samples were taken during the study and HPLC was performed to determine the metabolite-corrected arterial plasma radioactivity as input function. The ROI regions (cerebellum, frontal cortex, occipital cortex, pones, and thalamus) were drawn on co-registered MRI images. Results show that A fits to all ROI kinetics very well (R/sup 2/>0.99), and paired T-test for AIC showed there is no statistical significantly improvement of model fitting from B, C methods. The K/sub 1/ and DV images are of good image quality. Conclusion: A is best for ROI kinetic analysis and parametric imaging for DV and K/sub 1/.
- Open Access
- 1 December 2001
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 4 (04) , 385-391
Adjunctive high-dose glycine in the treatment of schizophrenia
Glycine is an agonist at brain N-methyl-d-aspartate receptors and crosses the blood-brain barrier following high-dose oral administration. In a previ
- 1 December 2001
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 4 (04) , 385-391
Open AccessAdjunctive high-dose glycine in the treatment of schizophrenia
Glycine is an agonist at brain N-methyl-d-aspartate receptors and crosses the blood-brain barrier following high-dose oral administration. In a previ